Jinze Li1, Lei Peng1, Dehong Cao2, Haocheng Gou3, Yunxiang Li1, Qiang Wei2. 1. Department of Urology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Sichuan, China. 2. Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. 3. Department of Otolaryngology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Sichuan, China.
Abstract
OBJECTIVE: We performed this meta-analysis to assess the association between metabolic syndrome (MetS) and benign prostatic hyperplasia (BPH). METHOD: We conducted extensive searches on the PubMed, Science and Cochrane Library to identify all articles. Outcomes including annual prostate growth rate, prostate volume (PV), International Prostate Symptom Score (IPSS), IPSS sub-scores (voiding and storage), prostate- specific antigen (PSA), maximum urine flow rate (Qmax), post-void residual urine volume (PVR) and quality of life (QoL) were assessed. RESULTS: 21 studies with 15,317 patients were included. Patients with MetS had higher annual prostate growth rate [weighted mean difference (WMD) = 0.79; p < .001], larger PV (WMD = 2.62; p < .001), lower Qmax (WMD = -0.48; p = .001) and more PVR (WMD = 8.28; p < .001). However, no significant differences were found between two groups in IPSS (WMD = 0.20; p = .37), IPSS-voiding (WMD = -0.05; p = .78), IPSS-storage (WMD = -0.22; p = .26), PSA (WMD = 0.04; p = .43), and QoL (WMD = -0.01; p = .70). CONCLUSIONS: The study suggested that MetS may be one of the risk factors for the clinical progress of BPH. However, further study is warranted to support these results.
OBJECTIVE: We performed this meta-analysis to assess the association between metabolic syndrome (MetS) and benign prostatic hyperplasia (BPH). METHOD: We conducted extensive searches on the PubMed, Science and Cochrane Library to identify all articles. Outcomes including annual prostate growth rate, prostate volume (PV), International Prostate Symptom Score (IPSS), IPSS sub-scores (voiding and storage), prostate- specific antigen (PSA), maximum urine flow rate (Qmax), post-void residual urine volume (PVR) and quality of life (QoL) were assessed. RESULTS: 21 studies with 15,317 patients were included. Patients with MetS had higher annual prostate growth rate [weighted mean difference (WMD) = 0.79; p < .001], larger PV (WMD = 2.62; p < .001), lower Qmax (WMD = -0.48; p = .001) and more PVR (WMD = 8.28; p < .001). However, no significant differences were found between two groups in IPSS (WMD = 0.20; p = .37), IPSS-voiding (WMD = -0.05; p = .78), IPSS-storage (WMD = -0.22; p = .26), PSA (WMD = 0.04; p = .43), and QoL (WMD = -0.01; p = .70). CONCLUSIONS: The study suggested that MetS may be one of the risk factors for the clinical progress of BPH. However, further study is warranted to support these results.
Authors: Paola Irene Ornaghi; Angelo Porreca; Marco Sandri; Alessandro Sciarra; Mario Falsaperla; Giuseppe Mario Ludovico; Maria Angela Cerruto; Alessandro Antonelli Journal: Prostate Cancer Prostatic Dis Date: 2022-07-22 Impact factor: 5.455
Authors: Asma Omran; Bianca M Leca; Eduard Oštarijaš; Natasha Graham; Ana Sofia Da Silva; Zoulikha M Zaïr; Alexander D Miras; Carel W le Roux; Royce P Vincent; Linda Cardozo; Georgios K Dimitriadis Journal: Ther Adv Endocrinol Metab Date: 2021-12-08 Impact factor: 3.565